Hormonal
Semaglutide demonstrates the greatest mean reduction in body weight among GLP-1RAs in psychiatric populations, significantly outperforming placebo and showing superior efficacy to liraglutide and exenatide in network meta-analysis.
Among GLP-1 medications, semaglutide (oral) appears to produce the most significant weight loss in patients with psychiatric conditions, averaging over 6 kg (13 lbs) loss. It is more effective than liraglutide or exenatide in this group. However, data is limited to one study, so discuss availability and cost with your provider.
A network meta-analysis confirmed that semaglutide showed the greatest mean reduction in body weight compared with placebo, with a mean difference of −6.14 kg (95% CI: −8.18 to −4.10; P < .001).
Why this rating
Based on network meta-analysis of included RCTs; limited by only one trial using oral semaglutide.
Source
GLP-1R Agonists for Weight Loss in Psychiatric Disorders: A Systematic Review and Meta-analysis
Klara Müller Alves et al. · Journal of the Endocrine Society · 2025
DOI 10.1210/jendso/bvaf150
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →